• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于 SEER 数据库构建并验证预测老年子宫浆液性癌患者预后的列线图模型。

Construction and validation of nomograms for predicting the prognosis of elderly patients with uterine serous carcinoma: a SEER-based study.

机构信息

Department of Gynecological Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, No. 17 Qihelou Street, Dongcheng District, Beijing, 100006, China.

出版信息

J Cancer Res Clin Oncol. 2023 Nov;149(16):14475-14492. doi: 10.1007/s00432-023-05174-3. Epub 2023 Aug 12.

DOI:10.1007/s00432-023-05174-3
PMID:37567988
Abstract

PURPOSE

To investigate the prognostic indicators, develop and verify nomograms for predicting overall survival (OS) and cancer-specific survival (CSS) in elderly patients with uterine serous carcinoma (USC).

METHODS

Data of eligible USC patients aged ≥ 65 years from 2004 to 2015 in the Surveillance, Epidemiology and End Results (SEER) database were collected for retrospective analysis. X-tile software was used to assess the optimal cut-off values. Univariate and multivariate Cox regression analyses were performed to explore the prognostic factors. Nomograms were developed to predict the probability of 1-, 3- and 5-year OS and CSS. Concordance indexes (c-index), receiver operating characteristic analysis and calibration curves were used to evaluate the model. Decision curve analysis (DCA) was introduced to examine the clinical value of the models.

RESULTS

Age, Federation International of Gynecology and Obstetrics stage, N stage, tumor size, number of lymph nodes resected, and adjuvant therapy were independent prognostic factors for OS and CSS. The C-indexes were 0.736 (OS), 0.754 (CSS) in the training set and 0.731 (OS), 0.759 (CSS) in the validation set. The area under the curve (AUCs) of OS and CSS for 1-, 3-, and 5-years all exceeded 0.75. The calibration plots for the probability of survival were in good agreement. As shown in DCA curves, the nomograms showed better discrimination power and higher net benefits than the 6th American Joint Committee on Cancer staging system.

CONCLUSIONS

The nomograms constructed based on prognostic risk factors could individually predict the prognosis of elderly USC patients and provide a reference for clinical decision-making.

摘要

目的

探讨预测老年子宫内膜浆液性癌(USC)患者总生存(OS)和癌症特异性生存(CSS)的预后指标,建立并验证列线图。

方法

回顾性分析 2004 年至 2015 年 SEER 数据库中年龄≥65 岁的 USC 患者数据。使用 X-tile 软件评估最佳截断值。采用单因素和多因素 Cox 回归分析探讨预后因素。建立预测 1、3 和 5 年 OS 和 CSS 概率的列线图。采用一致性指数(c-index)、接受者操作特征分析和校准曲线评估模型。引入决策曲线分析(DCA)评估模型的临床价值。

结果

年龄、国际妇产科联盟分期、N 分期、肿瘤大小、切除的淋巴结数量和辅助治疗是 OS 和 CSS 的独立预后因素。训练集的 C 指数分别为 0.736(OS)和 0.754(CSS),验证集的 C 指数分别为 0.731(OS)和 0.759(CSS)。OS 和 CSS 的 1、3 和 5 年 AUC 均超过 0.75。生存概率的校准图吻合良好。DCA 曲线显示,与第 6 版 AJCC 分期系统相比,列线图具有更好的判别能力和更高的净获益。

结论

基于预后风险因素构建的列线图可单独预测老年 USC 患者的预后,并为临床决策提供参考。

相似文献

1
Construction and validation of nomograms for predicting the prognosis of elderly patients with uterine serous carcinoma: a SEER-based study.基于 SEER 数据库构建并验证预测老年子宫浆液性癌患者预后的列线图模型。
J Cancer Res Clin Oncol. 2023 Nov;149(16):14475-14492. doi: 10.1007/s00432-023-05174-3. Epub 2023 Aug 12.
2
Development and validation of nomograms for predicting survival of locally advanced rectosigmoid junction cancer patients: a SEER database analysis.预测局部晚期直肠乙状结肠交界处癌患者生存的列线图的开发与验证:一项监测、流行病学和最终结果(SEER)数据库分析
Transl Cancer Res. 2025 May 30;14(5):2808-2821. doi: 10.21037/tcr-24-1810. Epub 2025 May 27.
3
Dynamic nomogram for predicting the overall survival and cancer-specific survival of patients with gastrointestinal neuroendocrine tumor: a SEER-based retrospective cohort study and external validation.预测胃肠道神经内分泌肿瘤患者总生存期和癌症特异性生存期的动态列线图:一项基于监测、流行病学和最终结果(SEER)数据库的回顾性队列研究及外部验证
Front Oncol. 2025 Jun 4;15:1594591. doi: 10.3389/fonc.2025.1594591. eCollection 2025.
4
A prognostic nomogram and risk classification system of elderly patients with extraosseous plasmacytoma: a SEER database analysis.基于 SEER 数据库分析的老年骨外浆细胞瘤患者预后列线图和风险分级系统。
J Cancer Res Clin Oncol. 2023 Dec;149(20):17921-17931. doi: 10.1007/s00432-023-05492-6. Epub 2023 Nov 13.
5
Nomogram for the prediction of the prognosis of patients with triple-negative invasive ductal carcinoma of breast after neoadjuvant chemotherapy.用于预测三阴性浸润性乳腺癌患者新辅助化疗后预后的列线图。
Sci Rep. 2025 Jul 1;15(1):21666. doi: 10.1038/s41598-025-05738-y.
6
Two web-based dynamically interactive nomograms and risk stratification systems for predicting survival outcomes and guiding treatment in non-metastatic nasopharyngeal carcinoma.用于预测非转移性鼻咽癌生存结局并指导治疗的两个基于网络的动态交互式列线图和风险分层系统。
J Cancer Res Clin Oncol. 2023 Nov;149(17):15969-15987. doi: 10.1007/s00432-023-05363-0. Epub 2023 Sep 8.
7
Prognostic nomogram for colorectal cancer patients with multi-organ metastases: a Surveillance, Epidemiology, and End Results program database analysis.多器官转移结直肠癌患者的预后列线图:监测、流行病学和最终结果计划数据库分析。
J Cancer Res Clin Oncol. 2023 Oct;149(13):12131-12143. doi: 10.1007/s00432-023-05070-w. Epub 2023 Jul 10.
8
Competing risk and random survival forest models for predicting survival in post-resection elderly stage I-III colorectal cancer patients.用于预测I-III期老年结直肠癌患者术后生存情况的竞争风险和随机生存森林模型
Sci Rep. 2025 Jul 7;15(1):24269. doi: 10.1038/s41598-025-05824-1.
9
Nomograms for Predicting Overall Survival and Cancer-Specific Survival of Small Cell Carcinoma of Ovary Patients: A Retrospective Cohort Study.预测卵巢小细胞癌患者总生存期和癌症特异性生存期的列线图:一项回顾性队列研究
World J Oncol. 2025 Jun;16(3):317-330. doi: 10.14740/wjon2543. Epub 2025 Apr 22.
10
Prognostic nomogram for external ear melanoma patients in the elderly: a SEER-based study.老年外耳道黑色素瘤患者的预后列线图:一项基于 SEER 的研究。
J Cancer Res Clin Oncol. 2023 Oct;149(13):12241-12248. doi: 10.1007/s00432-023-05098-y. Epub 2023 Jul 11.

本文引用的文献

1
Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology.子宫肿瘤,第1.2023版,美国国立综合癌症网络(NCCN)肿瘤学临床实践指南
J Natl Compr Canc Netw. 2023 Feb;21(2):181-209. doi: 10.6004/jnccn.2023.0006.
2
Practical management of older adults with cancer: geriatric oncology in Japan.老年癌症患者的实用管理:日本老年肿瘤学。
Jpn J Clin Oncol. 2022 Oct 6;52(10):1073-1081. doi: 10.1093/jjco/hyac118.
3
Association of Tumor Size With Myometrial Invasion, Lymphovascular Space Invasion, Lymph Node Metastasis, and Recurrence in Endometrial Cancer: A Meta-Analysis of 40 Studies With 53,276 Patients.
肿瘤大小与子宫内膜癌肌层浸润、淋巴管间隙浸润、淋巴结转移及复发的相关性:一项纳入40项研究共53276例患者的Meta分析
Front Oncol. 2022 Jun 2;12:881850. doi: 10.3389/fonc.2022.881850. eCollection 2022.
4
Endometrial cancer.子宫内膜癌。
Lancet. 2022 Apr 9;399(10333):1412-1428. doi: 10.1016/S0140-6736(22)00323-3.
5
Uterine serous carcinoma: role of surgery, risk factors and oncologic outcomes. Experience of a tertiary center.子宫浆液性癌:手术的作用、危险因素及肿瘤学结局。三级中心的经验。
Eur J Surg Oncol. 2022 Jan;48(1):268-274. doi: 10.1016/j.ejso.2021.10.011. Epub 2021 Oct 26.
6
Annual Report to the Nation on the Status of Cancer, Part 1: National Cancer Statistics.《全国癌症状况年度报告》第 1 部分:国家癌症统计。
J Natl Cancer Inst. 2021 Nov 29;113(12):1648-1669. doi: 10.1093/jnci/djab131.
7
Uterine serous carcinoma.子宫浆液性癌。
Gynecol Oncol. 2021 Jul;162(1):226-234. doi: 10.1016/j.ygyno.2021.04.029. Epub 2021 Apr 30.
8
Lymphovascular space invasion in endometrial carcinoma: Tumor size and location matter.子宫内膜癌中的淋巴管间隙浸润:肿瘤大小和位置至关重要。
Surg Oncol. 2021 Jun;37:101541. doi: 10.1016/j.suronc.2021.101541. Epub 2021 Mar 6.
9
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020:全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
10
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.ESGO/ESTRO/ESP 子宫内膜癌管理指南。
Int J Gynecol Cancer. 2021 Jan;31(1):12-39. doi: 10.1136/ijgc-2020-002230. Epub 2020 Dec 18.